Myriad Genetics, Inc. (MYGN)
NASDAQ: MYGN · Real-Time Price · USD
5.13
+0.05 (0.98%)
Apr 20, 2026, 1:31 PM EDT - Market open
Myriad Genetics Employees
Myriad Genetics had 2,700 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
2,700
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$305,370
Profits / Employee
-$135,519
Market Cap
484.49M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 2,700 | 0 | - |
| Dec 31, 2024 | 2,700 | 0 | - |
| Dec 31, 2023 | 2,700 | 100 | 3.85% |
| Dec 31, 2022 | 2,600 | 200 | 8.33% |
| Dec 31, 2021 | 2,400 | -300 | -11.11% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| NeoGenomics | 2,500 |
| OPKO Health | 2,275 |
| Fulgent Genetics | 1,315 |
| Castle Biosciences | 883 |
| CareDx | 765 |
| Burning Rock Biotech | 674 |
| FONAR | 535 |
| Biodesix | 334 |
MYGN News
- 4 days ago - Myriad Genetics to Deliver Six Abstracts, Including Two Podiums, at AACR 2026 - GlobeNewsWire
- 6 days ago - Myriad Genetics Expands Access for MyChoice Test to Prostate Cancer Patients in Japan - GlobeNewsWire
- 11 days ago - Myriad Genetics Underscores Commitment to Cancer Care Continuum with New Data Presentations at SGO Annual Meeting - GlobeNewsWire
- 4 weeks ago - Myriad Genetics Receives FDA Approval of the MyChoice CDx Test as the Companion Diagnostic for Zejula (niraparib) for Patients with Ovarian Cancer - GlobeNewsWire
- 7 weeks ago - Myriad Genetics Reports Fourth Quarter and Full-Year 2025 Financial Results; Reiterates 2026 Financial Guidance Reflecting Strengthened Execution - GlobeNewsWire
- 2 months ago - FirstGene Study Demonstrates High Analytical Sensitivity and Specificity for Each Component of the Test - GlobeNewsWire
- 2 months ago - Myriad Genetics to Release Fourth Quarter and Full Year 2025 Financial Results on February 23, 2026 - GlobeNewsWire
- 3 months ago - Myriad Genetics Announces Select Preliminary Fourth Quarter and Full Year 2025 Financial Results and Introduces Full Year 2026 Financial Guidance - GlobeNewsWire